Clinical Research
Filter News
Found 107,278 articles
-
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.
-
Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that their brexpiprazole failed to meet its primary endpoint in two Phase III clinical trials to treat manic episodes in patients with bipolar I disorder.
-
With 5 Gene Therapies Licensed From Penn, Passage Bio Launches With $115.5 Million Series A
2/15/2019
Philadelphia-based Passage Bio launched with a Series A financing round worth $115.5 million. It was led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures. -
WHO Plans to Develop Oversight Standards for Gene Editing Following Chinese Researcher’s Experiment
2/15/2019
Following international concern and outrage over a gene editing treatment of human embryos in China, the World Health Organization is taking action. -
February 15 Research Roundup: Rare Pediatric Cancer, Hibernating Hamsters, Prostate Cancer and More
2/15/2019
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Decipher Biosciences Announces Research Collaboration with Dendreon to Identify Genomic Drivers of Patient Response to Sipuleucel-T
2/15/2019
Decipher Biosciences, a leader in the field of urologic cancer genomics, today announced a research collaboration with Dendreon Pharmaceuticals
-
Investors are showing some love to AstraZeneca on this Valentine’s Day after the company posted strong year-end results. Shares of AstraZeneca are up more than 6 percent in premarket trading on the strength of the company’s financial results.
-
Novartis announced that the FDA approved the company’s Egaten to treat fascioliasis in patients six years of age and older. Novartis also inked a multi-target and multi-year collaboration with AbCellera.
-
Axovant Sciences, one of Vivek Ramaswamy’s biotech companies under the Roivant Sciences’ umbrella, is forming a company called Arvelle Therapeutics. Arvelle is a strategic transition of Axovant’s legacy small molecule team.Biopharmaceuticals
-
The pharma giant announced plans to expand its immuno-oncology program with three new Phase III trials following promising data from a combination of Keytruda and Lynparza and other agents.
-
Israel-based Teva Pharmaceutical is the largest generic drug company in the world. One in 10 drugs taken in the U.S. are manufactured by Teva, but as generic drug prices are forced downward, the company has struggled.
-
History shows just how slow public health officials, the federal government, regulators and pharmaceutical companies were to respond to the emergence of HIV in the 1980s. The reasons are numerous—it was a puzzling viral disease, it first appeared in what was then a largely stigmatized patient pop...
-
Blindfolded training could help doctors save young lives
2/14/2019
Doctors’ leadership in pediatric resuscitation improved most when they wore a blindfold during simulation training
-
Immunotherapy combination generates responses against castration-resistant metastatic prostate cancer
2/14/2019
Two checkpoint inhibitors provide early encouraging results for immunologically cold disease
-
Verastem Oncology Announces Publication of the Phase 2 DYNAMO Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology
2/14/2019
Verastem, Inc. announced that the results of the Phase 2 DYNAMO™ study, which evaluated COPIKTRA™ capsules in patients with indolent non-Hodgkin lymphoma who were refractory to both rituximab and chemotherapy or radioimmunotherapy, was published online in the [peer-reviewed] Journal of Clinical Oncology.
-
IEEE Completes Standards Family Intended to Provide Safe and Secure Medical Device Interoperability
2/14/2019
IEEE 11073-20701TM-2018 defines an architecture that binds the participant and communication model to the Web services data transport model defined in previous IEEE 11073™ standards.
-
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)
2/14/2019
Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy
-
IDT expands free next-day delivery service
2/14/2019
As an advocate for researchers in the genomics age, Integrated DNA Technologies (IDT) is expanding its courier zones to ensure that the highest-fidelity oligos are available in less time and at the same price, to more customers.
-
New Data Shows Community Health Workers Significantly Reduce Hospital Readmissions and Spending
2/14/2019
A program that uses community health workers (CHWs) to help chronically ill patients access care following hospitalization has cut readmission rates in half and reduced hospital spending by 35 percent for high-risk patients, according to new data from the University of Maryland St. Joseph Medical Center (UMSJMC) and Maxim Healthcare Services.
-
Competitor Analysis Study to Enhance Profitability and Prioritize Areas of Improvement for a Medical Devices Company - A Report by Infiniti Research
2/14/2019
A renowned market intelligence solution provider, Infiniti Research, has recently announced the completion of their latest competitor analysis study for a medical devices company.